Proactive oncology: How AI lung cancer detection is transforming care

• Lung cancer remains a leading cause of cancer-related death worldwide, driven by its high incidence and the frequency of late-stage diagnosis

• AI has the potential to reshape lung cancer care by enabling earlier diagnosis, more personalized treatment, and a more proactive approach to care delivery

• By combining human expertise with AI-driven insights, healthcare systems can strengthen decision-making across the lung cancer care continuum 

As the leading cause of cancer-related deaths worldwide, lung cancer remains one of the greatest challenges facing healthcare systems.¹ Care continues to operate largely within a reactive model, with many patients diagnosed at advanced stages, when treatment options are more limited, survival rates are lower, and the cost of care is highest.^1,2 

Earlier detection drives a critical stage shift, identifying lung cancers at more treatable stages for more timely intervention.³ Artificial intelligence (AI) is increasingly helping healthcare systems achieve this goal by supporting the transition from a reactive, treatment-focused approach to a proactive, risk-based model.⁴

As AI moves from pilot projects into routine clinical workflows, forward-looking healthcare leaders have an opportunity to leverage both clinical expertise and AI-powered insights to support decision-making across oncology pathways. From early detection and diagnosis of lung cancer to personalized treatment planning and ongoing monitoring, AI can help clinicians identify patients sooner and improve care delivery at scale.^3,4

Despite advances in screening and treatment, lung cancer remains one of the most significant clinical and economic challenges facing healthcare systems worldwide.^1,5 As the leading cause of cancer-related death globally, lung cancer continues to drive substantial morbidity, mortality, and healthcare spending, due in part to its high incidence and the frequency of delayed diagnosis.^1,6

The stage at which lung cancer is diagnosed has a profound impact on treatment availability and the cost of care.^2,7 Patients diagnosed with late-stage disease have a five-year survival rate of 10‒12%, compared with approximately 65‒67% for those diagnosed at an early-stage.⁵

Advanced disease also drives substantially higher treatment costs and healthcare resource utilization^_.2,7 In Europe alone, the annual cost of advanced non-small cell lung cancer (NSCLC) exceeds €3 billion, including expenditures related to primary care, hospitalization, and long-term treatment needs.⁸

Given this disproportionate burden, AI in lung cancer detection and management can no longer be dismissed as an experimental trend or pilot project; it must be recognized as an economic imperative.^5-8

Recognizing the importance of early detection of lung cancer, healthcare systems are increasingly interested in adopting AI in screening programs. From the stratification of at-risk populations to clinical decision support, AI can help organizations strengthen screening strategies and improve care pathways.⁴

Globally, lung cancer screening remains limited, with most countries yet to establish official guidelines.³ Moreover, wherever screening guidelines do exist, eligibility criteria systematically exclude a significant proportion of at-risk individuals. In the US, almost 65% of patients diagnosed with lung cancer fall outside current screening recommendations because they do not meet traditional age or smoking history criteria.⁹

To bridge this gap, healthcare systems are exploring AI-based risk assessment tools that extend beyond static eligibility checklists. By analyzing longitudinal individual data from routine laboratory results, medication histories, and other clinical variables, AI models can identify at-risk individuals who may benefit from screening despite falling outside conventional guidelines. This dynamic approach may help drive a strategic shift from passive observation to active intervention through electronic health record (EHR)-native screening-enrichment tools.^10-12

Furthermore, AI is also redefining computer-aided diagnosis through the use of advanced deep learning models that can assist in lung nodule detection, supporting a shift toward more personalized risk stratification with expert-level precision.^13,14 By assisting in the analysis of critical diagnostic and prognostic images, these tools can help clinicians distinguish between higher- and lower-risk findings, prioritize patients who may require additional evaluations, and mitigate the burden of false-positive results.^13-15  

By supporting faster, more informed clinical decision-making, AI has the potential to accelerate the pathway from detection to diagnosis. In this way, AI serves as a force multiplier in oncology care, ensuring patients receive targeted therapy in a timely manner.¹⁶

While AI is reshaping early detection of lung cancer, it is also playing a key role in how health care providers characterize and treat the disease after diagnosis. Across precision oncology, the focus is expanding beyond traditional biomarkers toward a more comprehensive understanding of each patient’s disease pathology.⁴

Pathomics is one of the developments driving this shift. Broadly defined as the field that applies machine learning to mine large-scale, objective data from scanned tissue sections, it bridges the gap between visual pathology and molecular biology. By converting routine biopsy images into high-dimensional digital datasets, AI can decode sub-visual morphological patterns, such as tissue architecture and immune cell infiltration. In some cases, these biological signals can be used to predict gene mutations directly from routine pathology slides, effectively reducing the lengthy process and steep financial costs of traditional molecular testing.^17-19   

AI is also advancing a more integrated approach to biomarker analysis through multimodal precision oncology. By combining pathology, radiomics, and transcriptomic data into a unified disease model, AI helps clinicians develop a macro-to-micro view of a patient’s disease.²⁰ This unified approach uniquely positions care teams to optimize prognostic accuracy and predict therapeutic responses, including the precise identification of patients most likely to benefit from immunotherapy.²⁰

From an infrastructure standpoint, this shift addresses the fiscal inefficiency of fragmented software through general-purpose foundation models. Trained on large-scale pathology datasets using self-supervised learning, these models capture broad biological representations that can be adapted to a range of clinical applications.^21,22 Crucially, foundation models require fewer data samples to achieve high accuracy, making precision oncology more scalable and enabling its deployment even for rare cancer subtypes that were not previously economically viable.²² 

Care and monitoring has also now extended beyond hospital walls to capture essential information through digital remote monitoring, including real-time data from wearable devices, or even circulating biomarkers. This continuous data stream allows for proactive, holistic interventions and enhances long-term postoperative surveillance.^23,24

For healthcare leaders, these tools highlight how AI can help extend the reach of precision oncology by extracting richer insights from existing clinical data, supporting hyper-personalized treatment decisions, and creating sustainable opportunities to scale advanced cancer care across broader patient populations.

While the technological possibilities are vast, the leap from high-performing lung cancer algorithms to scalable clinical assets requires more than technical performance. Healthcare systems need governance frameworks that can deliver real-world clinical value while supporting a trustworthy, transparent, and accountable partnership with AI.^21,25 

Central to this is how AI is positioned within clinical teams. AI must be integrated as a clinical decision-support tool within multidisciplinary team workflows, augmenting clinician capacity rather than replacing human expertise and oversight.^21,26 This model of hybrid intelligence can also help address growing oncology workforce pressures by automating time-consuming tasks, freeing up specialists to focus on higher-value clinical reasoning and decision-making.¹⁵ To be effective, however, this partnership must be built on a transparent, human-centered approach that supports accuracy, oversight, and patient-focused care.¹⁵ Ultimately, cultivating AI-literate clinical champions to spearhead integration, paired with strategic investments in continuous professional development, serves as the critical change-management engine that solidifies clinician trust.²⁶

To successfully navigate implementation challenges and gain clinician trust, developers must also adapt their models to prioritize transparency and operational fluidity. For example, the use of explainable AI (XAI) techniques, such as SHAP (SHapley Additive exPlanations) values and spatial heatmaps, give clinicians the tools to evaluate the physiological rationale behind an algorithm's prediction and reinforce clinical accountability.^27,28 In addition, to prevent operational friction, these insights must be delivered natively at the point of care by integrating AI directly into clinical workflows and EHRs using international interoperability standards like Health Level 7 Fast Healthcare Interoperability Resources (HL7 FHIR) to ensure scalable enterprise adoption.²⁹ Finally, algorithms must be validated within real-world settings, establishing targeted pilot programs to rigorously measure workflow integration, user trust, and baseline cost-effectiveness before executing a wider, enterprise-scale deployment.⁴

From a capital allocation perspective, while the upfront cost of AI integration across mid-to-large scale health systems is substantial, the long-term return on investment (ROI) is securely driven by a systemic "stage shift" toward early detection and a sharp reduction in unnecessary, high-cost procedures through personalized therapeutic planning.³⁰ To protect this fiscal runway, strategic planning must proactively mitigate operational friction by accounting for "hidden" expenses like intensive personnel training. To optimize financial agility, leadership should evaluate cloud-based AI-as-a-Service (AIaaS) deployment models, which effectively minimize upfront capital outlays while ensuring scalable, equitable access to advanced diagnostic capabilities across both flagship hospitals and resource-constrained community facilities. 

Together, these strategies can help healthcare organizations establish the governance, workflow integration, and clinician confidence needed to scale AI-enabled clinical decision support. By focusing on both technology and change management, healthcare leaders can create a foundation for sustainable adoption and long-term value creation.

The future of lung cancer care will depend on the ability of  healthcare systems to move beyond reactive treatment toward proactive, earlier detection and targeted intervention. AI is emerging as a key driver of this transformation, with scalable applications that extend across the entire oncology care continuum, from risk stratification and early detection to precision oncology and clinical decision support transforming lung cancer services.⁴

Realizing the full value of AI requires the right foundations, including trusted governance frameworks, seamless workflow integration, and strong partnerships between clinicians and AI-enabled tools.^4,21,25 By leveraging AI to drive a stage shift toward earlier intervention, healthcare leaders can  reduce the clinical and economic burden associated with advanced disease, and alleviate rising operational and financial pressures.^2-4